VolitionRX Ltd (VNRX)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

13215 BEE CAVE PARKWAY AUSTIN, TX 78738

VolitionRX is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats. VolitionRX is managed by a well-respected team with extensive experience in diagnostics and commercialization.

Data as of 2020-08-01
Market Cap149.311 Million Shares Outstanding46.226 Million Avg 30-day Volume895.248 Thousand
P/E Ratio Dividend Yield EPS-0.43
Price/Sales8464.35 Price cash flow ratio Price free cash flow ratio-12.9
Book Value0.2 Price to Tangible Book17.15 Alpha-0.0
Short Interest Ratio1.2 % Short Interest to Float3.0 R-squared0.152076
BETA1.7117 52-week High/Low6.84 / 2.22 Stddev0.188849
View SEC Filings from VNRX instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 1 0 (0.0%)
13F Filers holding this stock: 32 4 (0.26%)
Aggregate 13F shares on 03/31/2020: 3.391 Million 685.16 Thousand
Aggregate 13F shares on 12/31/2019: 3.165 Million 623.525 Thousand
Percent change: 7.15% 9.88%
Funds creating new positions: 7 1
Funds Adding to an existing position: 7
Funds closing out their position: 10 3
Funds reducing their position: 2
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding VNRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding VNRX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

220 Thousand total shares from 6 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MICALLEF JACOB VINCENT CHIEF SCIENTIFIC OFFICER

  • Officer
0 2020-07-27 3

REYNOLDS CAMERON JOHN PRESIDENT AND CEO

  • Officer
  • Director
2,184,167 2020-07-21 4

FAULKES MARTIN CHARLES

  • Director
1,926,943 2020-07-21 5

ROOTSAERT RODNEY GERARD SECRETARY

  • Officer
1,028,116 2020-07-21 3

INNES GUY ARCHIBALD

  • Director
0 2020-04-13 1

COLMAN ALAN

  • Director
0 2020-04-13 1

TERRELL JASON BRADLEY MD CHIEF MEDICAL OFFICER

  • Officer
0 2020-04-13 3

FUTCHER EDWARD

  • Director
394,250 2020-04-13 1

VANSTON DAVID CECIL CHIEF FINANCIAL OFFICER

  • Officer
0 2020-04-13 2

BARNES PHILLIP

  • Director
0 2020-04-13 2

KWAY JASMINE CEO-SINGAPORE VOLITION

  • Officer
0 2020-04-13 2

EIGHT CORP LTD

COTTERFORD CO LTD

  • 10% Owner
12,045,332 2019-10-01 2

SKAFF HABIB

  • Director
0 2019-02-11 0

GAETAN MICHEL

  • MANAGER-BELGIAN VOLITION SPR
0 2018-12-20 0

KRATOCHVIL DAVID MATTHEW CHIEF FINANCIAL OFFICER

  • Officer
10,000 2016-10-05 0

ROOTSAERT RODNEY GERARD SECRETARY

CONCORD INTERNATIONAL INC.

  • Officer
  • 10% Owner
1,004,088 2014-09-03 0

O'CONNELL MICHAEL JAMES CHIEF FINANCIAL OFFICER

  • Officer
0 2014-07-01 0

MAGALLANO ALEXANDER B. CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
100,000 2008-04-16 0

PEREZ RUDY BELLOY TREASURER & SECRETARY

  • Officer
100,000 2008-04-16 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

MICALLEF JACOB VINCENT - Officer CHIEF SCIENTIFIC OFFICER

2020-07-27 G 55,000 a 55,000 0.00 direct

MICALLEF JACOB VINCENT - Officer CHIEF SCIENTIFIC OFFICER

2020-07-27 G 65,000 a 65,000 0.00 direct

MICALLEF JACOB VINCENT - Officer CHIEF SCIENTIFIC OFFICER borlaug limited

2020-07-27 G 55,000 d 0 0.00 indirect

MICALLEF JACOB VINCENT - Officer CHIEF SCIENTIFIC OFFICER borlaug limited

2020-07-27 G 65,000 d 0 0.00 indirect

MICALLEF JACOB VINCENT - Officer CHIEF SCIENTIFIC OFFICER

2020-07-27 G 65,000 a 65,000 0.00 direct

MICALLEF JACOB VINCENT - Officer CHIEF SCIENTIFIC OFFICER borlaug limited

2020-07-27 G 65,000 d 0 0.00 indirect

ROOTSAERT RODNEY GERARD - Officer SECRETARY

2020-07-21 M 30,000 $2.50 a 39,828 1,028,116.00 direct

REYNOLDS CAMERON JOHN - Director - Officer PRESIDENT AND CEO

2020-07-21 M 50,000 d 0 2,184,167.00 direct

REYNOLDS CAMERON JOHN - Director - Officer PRESIDENT AND CEO

2020-07-21 M 50,000 $3.00 a 1,186,000 2,184,167.00 direct

FAULKES MARTIN CHARLES - Director

2020-07-21 M 30,000 d 0 1,926,943.00 direct

FAULKES MARTIN CHARLES - Director

2020-07-21 M 30,000 $3.00 a 1,597,120 1,926,943.00 direct

ROOTSAERT RODNEY GERARD - Officer SECRETARY

2020-07-21 M 30,000 d 0 1,028,116.00 direct

ROOTSAERT RODNEY GERARD - Officer SECRETARY

2020-07-21 M 30,000 $3.00 a 46,214 1,028,116.00 direct

REYNOLDS CAMERON JOHN - Director - Officer PRESIDENT AND CEO

2020-07-21 M 50,000 d 0 2,184,167.00 direct

REYNOLDS CAMERON JOHN - Director - Officer PRESIDENT AND CEO

2020-07-21 F 40,273 $3.95 d 1,136,000 2,184,167.00 direct

FAULKES MARTIN CHARLES - Director

2020-07-21 M 30,000 d 0 1,926,943.00 direct

FAULKES MARTIN CHARLES - Director

2020-07-21 F 24,164 $3.95 d 1,567,120 1,926,943.00 direct

ROOTSAERT RODNEY GERARD - Officer SECRETARY

2020-07-21 M 30,000 d 0 1,028,116.00 direct

ROOTSAERT RODNEY GERARD - Officer SECRETARY

2020-07-21 F 23,614 $3.95 d 16,214 1,028,116.00 direct

REYNOLDS CAMERON JOHN - Director - Officer PRESIDENT AND CEO

2020-07-21 F 43,627 $3.95 d 1,142,373 2,184,167.00 direct

REYNOLDS CAMERON JOHN - Director - Officer PRESIDENT AND CEO

2020-07-21 M 50,000 $2.50 a 1,176,273 2,184,167.00 direct

FAULKES MARTIN CHARLES - Director

2020-07-21 F 26,177 $3.95 d 1,570,943 1,926,943.00 direct

FAULKES MARTIN CHARLES - Director

2020-07-21 M 30,000 $2.50 a 1,591,284 1,926,943.00 direct

ROOTSAERT RODNEY GERARD - Officer SECRETARY

2020-07-21 F 25,816 $3.95 d 20,398 1,028,116.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments